immunotherapy and alternative therapy for cancer.pptx
•Download as PPTX, PDF•
0 likes•21 views
This document summarizes the process of CAR T-cell immunotherapy. T cells are isolated from a cancer patient via leukapheresis and infected with a viral vector containing the gene for a chimeric antigen receptor (CAR). The CAR gene modifies the T cells to target specific tumor antigens. The CAR T cells are expanded in culture and then infused back into the patient. Once in the patient, the CAR T cells activate and proliferate upon recognition of tumor cells. They then work to destroy tumor cells through immune activation pathways involving cytokines and cytotoxic mechanisms like perforin pores and granzyme activity.
Report
Share
Report
Share
![Viral vector
leukapheresis
Isolation of T cells
Infection of T cells with
viral vector
CAR (chimeric
antigen
receptor) gene
Autologous T cell
CAR
Expansion
of CAR T
cells CAR T cell culture
Activated
macrophage
Activated
Dendritic cell
Cancer
patient
infusion of
CAR T cells to
patient
Immune
activation and
destruction of
tumor cells by
CAR T cells
Tumor cell
Activated
NK cell
IL-2
IL-12
IL-6
perforins
Perforin pore
Granzyme
Increased
expression of
death receptors
CAR T cell
References
Feins, S., Kong, W., Williams, E.F., Milone, M.C. and Fraietta, J.A. (2019). An introduction to chimeric antigen receptor (CAR) T‐cell
immunotherapy for human cancer. American Journal of Hematology, [online] 94(S1), pp.S3–S9. doi:10.1002/ajh.25418.
Li, J., Li, W., Huang, K., Zhang, Y., Kupfer, G. and Zhao, Q. (2018). Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors:
lessons learned and strategies for moving forward. Journal of Hematology & Oncology, [online] 11(1). doi:10.1186/s13045-018-0568-6.
WBCs](https://image.slidesharecdn.com/immunotherapyandalternativetherapyforcancer-230228090056-763def7a/85/immunotherapy-and-alternative-therapy-for-cancer-pptx-1-320.jpg)
Recommended
Tumour immunology leture notes
This document provides an overview of tumor immunology, including definitions of cancer and carcinogenesis, tumor antigens, the immune response to cancer, and mechanisms by which tumors escape the immune system. It discusses how tumors stimulate an immune response through antigens but also ways they can evade immunity, such as through low immunogenicity, antigen modulation, and immune suppression. It describes experimental evidence for tumor antigens and the immune response against tumors.
Immunotoxins_MJ.ppt
This document discusses a proposed study to target cancer stem cells in leukemia using tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-based immunotoxins. The objectives are to identify and characterize cancer stem cells from leukemia cell lines and patients, construct recombinant TRAIL-based chimeric proteins to selectively target these cancer stem cells, and test the efficacy and selectivity of the proteins. Cancer stem cells are resistant to chemotherapy and responsible for leukemia recurrence. TRAIL selectively induces apoptosis in cancer cells and has advantages over chemotherapy. The study aims to develop dual receptor targeted immunotoxins linking TRAIL to the interleukin-2 receptor to more effectively treat leukemia by eliminating drug-resistant cancer stem cells.
2010_Udyavar
1) T-cell receptor (TCR) gene therapy redirects T lymphocytes for cancer immunotherapy by introducing rearranged TCR genes, allowing the T cells to target tumors.
2) Successful TCR gene therapy requires consideration of TCR specificity and affinity, optimal gene constructs, the types of T cells used, and the survival and activity of the modified T cells.
3) The review highlights the rationale and experience with TCR gene therapy and new approaches to enhance its effectiveness.
Engineered T Cell Therapy for
Gynecologic Malignancies
Challenges and Opportu...
This document discusses engineered T cell therapy for gynecologic malignancies. It begins by introducing common gynecologic cancers and recent successes of adoptive T cell therapy using engineered T cells for other cancers. The document then summarizes two main types of engineered T cells - T cell receptor modified T cells (TCR-Ts) and chimeric antigen receptor T cells (CAR-Ts) - and their mechanisms of action. Finally, it explores opportunities to apply these engineered T cell therapies to treat gynecologic cancers based on preclinical research and early clinical trials.
Discover Personalized Medicine: Oliver Dorigo, MD, PhD
1) Dr. Oliver Dorigo presented on using the immune system to target ovarian cancer.
2) Immunotherapy approaches such as immune checkpoint inhibitors that target PD-1 and PDL1 have shown promising responses in ovarian cancer patients.
3) Adoptive cell transfer therapy, which uses genetically modified T cells targeted to ovarian cancer antigens like NY-ESO-1, shows potential as a personalized treatment approach.
Epitope base editing CD45 in hematopoietic cells enables universal blood canc...
CD4 Epitope base editing
Active Immunotherapy in cancer – Current Status_Crimson Publishers
Immunotherapy is a fourth pillar in cancer management after surgery, radiotherapy and chemotherapy. Active immunotherapy works by inducing antigen specific immune response following its administration while checkpoint inhibitor works by reducing tumor induced immunosuppression and thereby utilizing pre-existing immune response. Adoptive cell therapy (ACT) is a type of personalized therapy wherein cells are harvested from a patient, expanded and reintroduced. The T cells are genetically modified in chimeric antigen receptor T cell (CAR-T) therapy while tumor infiltrating cells are used in in ACT and dendritic cells are used in dendritic cell (DC) vaccine. Vaccine induces T cell response against the antigen of interest. T cells available following single administration are higher in ACT compared to vaccine approach. CAR-T cells are found useful in refractory large B-cell lymphoma and refractory large B-cell precursor acute lymphoblastic leukemia. ACT is found useful in melanoma. Vaccines are approved for melanoma as a monotherapy and for non-small cell lung cancer in combination with chemotherapy.
Novel_technologies_and _emerging_biomarkers_for_personalized_cancer_immunothe...
This document reviews emerging biomarkers and technologies for personalized cancer immunotherapy. It discusses how our understanding of the immune system's role in cancer has evolved over the last century. Checkpoint blockade therapies have shown success in treating some cancers, but biomarkers are still needed to identify which patients will benefit and experience fewer side effects. The document explores biomarkers for CTLA-4 blockade and the PD-1/PD-L1 axis. It also discusses novel technologies that could help discover new biomarkers and advance precision medicine in cancer immunotherapy.
Recommended
Tumour immunology leture notes
This document provides an overview of tumor immunology, including definitions of cancer and carcinogenesis, tumor antigens, the immune response to cancer, and mechanisms by which tumors escape the immune system. It discusses how tumors stimulate an immune response through antigens but also ways they can evade immunity, such as through low immunogenicity, antigen modulation, and immune suppression. It describes experimental evidence for tumor antigens and the immune response against tumors.
Immunotoxins_MJ.ppt
This document discusses a proposed study to target cancer stem cells in leukemia using tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-based immunotoxins. The objectives are to identify and characterize cancer stem cells from leukemia cell lines and patients, construct recombinant TRAIL-based chimeric proteins to selectively target these cancer stem cells, and test the efficacy and selectivity of the proteins. Cancer stem cells are resistant to chemotherapy and responsible for leukemia recurrence. TRAIL selectively induces apoptosis in cancer cells and has advantages over chemotherapy. The study aims to develop dual receptor targeted immunotoxins linking TRAIL to the interleukin-2 receptor to more effectively treat leukemia by eliminating drug-resistant cancer stem cells.
2010_Udyavar
1) T-cell receptor (TCR) gene therapy redirects T lymphocytes for cancer immunotherapy by introducing rearranged TCR genes, allowing the T cells to target tumors.
2) Successful TCR gene therapy requires consideration of TCR specificity and affinity, optimal gene constructs, the types of T cells used, and the survival and activity of the modified T cells.
3) The review highlights the rationale and experience with TCR gene therapy and new approaches to enhance its effectiveness.
Engineered T Cell Therapy for
Gynecologic Malignancies
Challenges and Opportu...
This document discusses engineered T cell therapy for gynecologic malignancies. It begins by introducing common gynecologic cancers and recent successes of adoptive T cell therapy using engineered T cells for other cancers. The document then summarizes two main types of engineered T cells - T cell receptor modified T cells (TCR-Ts) and chimeric antigen receptor T cells (CAR-Ts) - and their mechanisms of action. Finally, it explores opportunities to apply these engineered T cell therapies to treat gynecologic cancers based on preclinical research and early clinical trials.
Discover Personalized Medicine: Oliver Dorigo, MD, PhD
1) Dr. Oliver Dorigo presented on using the immune system to target ovarian cancer.
2) Immunotherapy approaches such as immune checkpoint inhibitors that target PD-1 and PDL1 have shown promising responses in ovarian cancer patients.
3) Adoptive cell transfer therapy, which uses genetically modified T cells targeted to ovarian cancer antigens like NY-ESO-1, shows potential as a personalized treatment approach.
Epitope base editing CD45 in hematopoietic cells enables universal blood canc...
CD4 Epitope base editing
Active Immunotherapy in cancer – Current Status_Crimson Publishers
Immunotherapy is a fourth pillar in cancer management after surgery, radiotherapy and chemotherapy. Active immunotherapy works by inducing antigen specific immune response following its administration while checkpoint inhibitor works by reducing tumor induced immunosuppression and thereby utilizing pre-existing immune response. Adoptive cell therapy (ACT) is a type of personalized therapy wherein cells are harvested from a patient, expanded and reintroduced. The T cells are genetically modified in chimeric antigen receptor T cell (CAR-T) therapy while tumor infiltrating cells are used in in ACT and dendritic cells are used in dendritic cell (DC) vaccine. Vaccine induces T cell response against the antigen of interest. T cells available following single administration are higher in ACT compared to vaccine approach. CAR-T cells are found useful in refractory large B-cell lymphoma and refractory large B-cell precursor acute lymphoblastic leukemia. ACT is found useful in melanoma. Vaccines are approved for melanoma as a monotherapy and for non-small cell lung cancer in combination with chemotherapy.
Novel_technologies_and _emerging_biomarkers_for_personalized_cancer_immunothe...
This document reviews emerging biomarkers and technologies for personalized cancer immunotherapy. It discusses how our understanding of the immune system's role in cancer has evolved over the last century. Checkpoint blockade therapies have shown success in treating some cancers, but biomarkers are still needed to identify which patients will benefit and experience fewer side effects. The document explores biomarkers for CTLA-4 blockade and the PD-1/PD-L1 axis. It also discusses novel technologies that could help discover new biomarkers and advance precision medicine in cancer immunotherapy.
TIL (Tumor Infiltrating Lymphocyte) therapy.pptx
In the ongoing battle against cancer, medical researchers are constantly exploring innovative treatments that can effectively target and eliminate malignant cells while sparing healthy tissue. Among these emerging therapies, tumor-infiltrating lymphocyte (TIL) therapy stands out as a promising approach that harnesses the body's own immune system to combat cancer.
Understanding Tumor-Infiltrating Lymphocytes
TIL therapy revolves around a crucial component of the immune system: lymphocytes, specifically T cells. These specialized white blood cells play a pivotal role in identifying and destroying abnormal cells, including cancerous ones. However, in many cases, tumors manage to evade the immune system's surveillance mechanisms, allowing them to grow and spread unchecked.
TIL therapy aims to overcome this evasion by extracting immune cells from a patient's tumor tissue, where T cells have already infiltrated the cancerous mass. These TILs are then isolated, expanded, and activated outside the body before being reintroduced into the patient. By bolstering the immune response with a concentrated dose of tumor-targeting T cells, this therapy seeks to tip the balance in favor of the immune system, enabling it to mount a more effective attack against the cancer.
The Therapeutic Process
The journey of TIL therapy begins with the surgical removal of a tumor specimen from the patient. From this tissue, TILs are isolated using specialized techniques in the laboratory. These extracted T cells are then cultured and expanded to increase their numbers dramatically, creating a robust army of immune cells primed for combat.
Once a sufficient quantity of activated TILs has been generated, they are infused back into the patient's bloodstream. Due to specific molecular signals sent out by cancer cells, these engineered immune cells focus on the tumor site as they travel throughout the body. Upon reaching their destination, the TILs launch a multifaceted assault, directly attacking malignant cells and recruiting other components of the immune system to join the fight.
The Promise of TIL Therapy
One of the most compelling aspects of TIL therapy is its potential to achieve durable responses in patients with advanced or metastatic cancers. Clinical studies have shown promising results across a range of cancer types, including melanoma, cervical cancer, and gastrointestinal malignancies. In some cases, patients who have exhausted conventional treatment options have experienced remarkable tumor regression and prolonged survival following TIL therapy.
Connect with CancerFax if you wish to avail of TIL therapy in China.
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
This document discusses various cancer immunotherapy approaches for treating high grade glial tumors, including tumor immunotherapy using exogenously produced and reinfused cytotoxic T cells, depletion of immunosuppressive Treg cells, genetic production and propagation of T cells carrying tumor-antigen specific T cell receptors, vaccination approaches using peptide vaccines, dendritic cell vaccines, and autologous/whole tumor cell vaccines. It also discusses the advantages and disadvantages of different vaccine types as well as ways to augment antitumor immunity, including through adoptive T cell therapy, checkpoint inhibitors, cytokines, and other agents.
Pharm immuno14&15 cancer & transplantpor
The document summarizes key concepts in immunology related to cancer and organ transplants. It discusses how the immune system can recognize and respond to tumors, mechanisms by which tumors evade immune detection, and approaches to cancer immunotherapy. It also covers immune mechanisms of graft rejection, types of transplants, and strategies to prevent rejection through immunosuppression.
SCT60103 Group 2 Presentation
A normal cell can be transformed into a cancerous cell. Discuss the therapeutic strategies that are employed to target the cellular transformation process for cancer prevention and treatment.
Tumourclasss
1. A tumor is abnormal tissue consisting of genetic-altered cells that can arise due to mutations or environmental factors like radiation or infections.
2. The immune system can recognize and destroy early cancer cells but tumors evolve mechanisms to evade the immune response through loss of antigen presentation or secretion of factors that suppress T cells.
3. Immunotherapy aims to enhance anti-tumor immunity through vaccines, adoptive cell therapies, monoclonal antibodies, or cytokines to help the immune system overcome tumor evasion and eliminate cancer cells in a targeted manner with less toxicity than other treatments.
CAR-T Cell Therapy (Aliakbar Esfahani,Bsc of clinical laboratory sciences)
CAR-T Cell Therapy (Aliakbar Esfahani,Bsc of clinical laboratory sciences)Mashhad University of Medical Sciences
This document discusses CAR-T cell therapy. It provides information on CAR-T cells, including that they are T-cells (CD8+ or CD4+) equipped with a chimeric antigen receptor (CAR) that allows them to target tumor cells. The document outlines the steps of CAR-T cell therapy, which involves leukapheresis to collect T-cells, activating and engineering the T-cells to express the CAR, then infusing the CAR-T cells back into the patient to target tumor cells. The document also discusses components of CARs like co-stimulatory domains that enhance T-cell activation and survival.CAR-T CELLS IN SOLID TUMORS
T cells genetically engineered to express chimeric antigen receptors (CAR) have proven an impressive therapeutic activity in patients with certain subtypes of B cell leukaemia or lymphoma, with promising efficacy also demonstrated in patients with multiple myeloma. However, in patients with solid tumors, objective responses to CAR-T cell therapy remain sporadic and transient. Key challenges relating to CAR T cells include the lack of tumor exclusive target, restricted CAR-T cell trafficking to tumor sites, antigen escape and heterogeneity as well as a highly immunosuppressive microenvironment. In this report, we review the current state of the CAR-T technologies as a clinical treatment in solid tumor and we highlight the preclinical innovative designs of novel CAR T cell products that are being developed to increase and expand the clinical benefits of these treatments in patients with solid malignancies.
Crosstalk Between Cancer Inflammation and Immunity: Host Defense Webinar Seri...
This slidedeck will review the mechanisms of anticancer immune responses, which include immune checkpoints and the cross-talk between cancer cells and the cellular mediators of inflammation and immunity. The impact of gut microbiota in eliciting the immune responses against cancer and modulating the effects of drugs will also be discussed. In addition, we will discuss the roles of long non-coding RNAs (lncRNAs) in cancer progression and immune responses. Research tools and therapeutic strategies are also presented.
Immunological Abnormalities in Liver Carcinoma
1) Hepatocellular carcinoma (HCC) has a poor prognosis and limited treatment options. While immune therapies show promise, the response of HCC has been unsatisfactory due to its immunosuppressive microenvironment.
2) Dendritic cells activate T cells to target cancer cells, but in HCC various immune cells and cytokines like regulatory T cells and TGF-β promote immune suppression.
3) Future therapies aim to modulate this microenvironment through vaccines, adoptive cell transfer, immune checkpoint blockade, and other approaches to achieve effective anti-tumor immunity against HCC.
Ras Vaccine prevents skin cancer (Nasti Timares)JI 2015
This document summarizes research on using vaccination to prevent skin tumors induced by chemical carcinogens like DMBA. The researchers found that DMBA exposure causes a mutation in the H-ras oncogene in preneoplastic skin cells within 24 hours. They developed vaccines targeting the mutant H-ras epitope that generated cytotoxic T cells, which eliminated preneoplastic cells and protected against tumor formation when administered before or after DMBA exposure. Adoptive transfer of cells from vaccinated mice regressed established tumors, overcoming tumor-mediated immunosuppression. These findings support further evaluation of targeting early oncogenic mutations to boost immunosurveillance and block tumor development.
SF AACR submitted abstract
This study monitored in vitro immune responses in a healthy donor to various self-antigens presented using dendritic cells. Adenoviral vectors were used to deliver tumor antigens like melan A/MART-1, gp100, NY-ESO-1, HER2, and cytokeratin 18 or HLA-A2 epitope peptides to antigen presenting cells. Analysis of T cell surface markers, cytokine release, and cytolytic activity revealed that gp100 stimulation led to a predominant IFN+ CD8+ CD56- T cell population within three restimulations, whereas MART-1 stimulation resulted in an equal division of IFN+ cells between CD4+ and CD8+ CD56- T cells. Comprehen
Anticancer immunity 2013
The document discusses anti-cancer immunity from an immune perspective. It covers topics like cancer immunoediting, how cancer cells become resistant to immune elimination, and different anti-cancer immunotherapy strategies. Specifically:
1) Cancers evolve to escape immune detection through a process called immunoediting where immunogenic tumor cells are eliminated, leaving behind immune-resistant cells.
2) Tumor cells can become resistant by losing antigen expression or failing to present antigens on MHC molecules, allowing them to evade T cell attack.
3) Popular immunotherapies include immune checkpoint blockade, adoptive cell transfer, vaccines, and strategies that non-specifically stimulate the immune system.
May r.j.-et-al.-2007-clinical-cancer-research
This document summarizes a study identifying three HLA class II peptide epitopes from the Wilms' tumor 1 (WT1) oncoprotein that stimulate CD4+ T cell responses. One peptide (122-140) also contains a previously identified CD8+ epitope (126-134) and was modified to improve its ability to induce both CD4+ and CD8+ T cell responses against WT1-expressing tumor cells. Dendritic cells pulsed with these WT1 peptides were able to stimulate peptide-specific CD4+ T cell responses and cross-priming experiments showed the dendritic cells could present the peptides after processing tumor cell lysates. These WT1 CD4+ peptides may be useful for inclusion in
Immune cell therapy
Immunotherapy is defined as the approach to treating
cancer by generating or augmenting an immune
response against it.
Genetic deletion of HVEM in a leukemia B cell line promotes a preferential in...
Introduction: A high frequency of mutations affecting the gene encoding Herpes Virus Entry Mediator (HVEM, TNFRSF14) is a common clinical finding in a wide variety of human tumors, including those of hematological origin.
Methods: We have addressed how HVEM expression on A20 leukemia cells influences tumor survival and its involvement in the modulation of the anti-tumor immune responses in a parental into F1 mouse tumor model of hybrid resistance by knocking-out HVEM expression. HVEM WT or HVEM KO leukemia cells were then injected intravenously into semiallogeneic F1 recipients and the extent of tumor dissemination was evaluated.
Results: The loss of HVEM expression on A20 leukemia cells led to a significant increase of lymphoid and myeloid tumor cell infiltration curbing tumor progression. NK cells and to a lesser extent NKT cells and monocytes were the predominant innate populations contributing to the global increase of immune infiltrates in HVEM KO tumors compared to that present in HVEM KO tumors. In the overall increase of the adaptive T cell immune infiltrates, the stem cell-like PD-1- T cells progenitors and the effector T cell populations derived from them were more prominently present than terminally differentiated PD-1+ T cells.
Conclusions: These results suggest that the PD-1- T cell subpopulation is likely to be a more relevant contributor to tumor rejection than the PD-1+ T cell subpopulation. These findings highlight the role of co-inhibitory signals delivered by HVEM upon engagement of BTLA on T cells and NK cells, placing HVEM/BTLA interaction in the spotlight as a novel immune checkpoint for the reinforcement of the anti-tumor responses in malignancies of hematopoietic origin.
Seminar-Oncolytic viruses
This document provides an overview of oncolytic viruses (OVs) as a potential cancer treatment. It discusses how OVs selectively target and kill cancer cells through direct lysis and stimulation of anti-tumor immunity. The mechanisms of OV action and various strategies for enhancing their efficacy are described, such as arming OVs with immunostimulatory genes or anti-angiogenic factors. Several OVs currently in clinical trials are highlighted, including T-VEC which was approved in 2015 for melanoma treatment. The document concludes that OVs show promise as a novel cancer immunotherapy but further research is still needed to address issues like viral resistance and toxicity.
Basics of immunotherapy in colorectal cancer
Basic immunology of colorectal cancer. Highlight the future role of immunotherapy in Colorectal cancer.
Immunological Role of Th-9 cell
This document summarizes a presentation on T-helper 9 (Th9) cells, a relatively new member of the Th cell family. The presentation outlines that Th9 cells differentiate from naive CD4+ T cells in response to TGF-β and IL-4 cytokines. Th9 cells secrete IL-9 and play roles in allergies, parasite expulsion, autoimmune diseases, cancer, and other conditions. While Th9 cells can promote inflammation and tissue damage, they also help expel parasites and inhibit tumor growth. Further research is needed to understand Th9 cell mechanisms and potential immunotherapy applications.
Tumour Immunology
The document discusses cancer immunosurveillance and immunoediting. It describes how the immune system plays an important role in protecting against cancer development through elimination of nascent tumor cells and shaping of tumor immunogenicity. There are three phases - elimination, equilibrium, and escape. In the elimination phase, innate and adaptive immunity work to eliminate cancer cells. In the equilibrium phase, immune editing sculpts less immunogenic tumor cells. Eventually, tumor cells can escape immune destruction in the escape phase through mechanisms to avoid detection.
Tumour immunology
The document discusses cancer immunosurveillance and immunoediting. It describes how the immune system plays an important role in controlling cancer development through 3 phases - elimination, equilibrium, and escape. In the elimination phase, innate and adaptive immunity work to eliminate cancer cells. Some cancer cells may survive this phase if they acquire properties to evade the immune system, entering the equilibrium phase. Eventually, in the escape phase, cancer cells are able to avoid immune destruction through various mechanisms and form clinically detectable tumors. Immunotherapy aims to enhance the immune response against cancer cells.
原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样
原版纸张【微信：741003700 】【(carleton毕业证书)卡尔顿大学毕业证】【微信：741003700 】学位证，留信认证（真实可查，永久存档）offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原海外各大学 Bachelor Diploma degree, Master Degree Diploma
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
More Related Content
Similar to immunotherapy and alternative therapy for cancer.pptx
TIL (Tumor Infiltrating Lymphocyte) therapy.pptx
In the ongoing battle against cancer, medical researchers are constantly exploring innovative treatments that can effectively target and eliminate malignant cells while sparing healthy tissue. Among these emerging therapies, tumor-infiltrating lymphocyte (TIL) therapy stands out as a promising approach that harnesses the body's own immune system to combat cancer.
Understanding Tumor-Infiltrating Lymphocytes
TIL therapy revolves around a crucial component of the immune system: lymphocytes, specifically T cells. These specialized white blood cells play a pivotal role in identifying and destroying abnormal cells, including cancerous ones. However, in many cases, tumors manage to evade the immune system's surveillance mechanisms, allowing them to grow and spread unchecked.
TIL therapy aims to overcome this evasion by extracting immune cells from a patient's tumor tissue, where T cells have already infiltrated the cancerous mass. These TILs are then isolated, expanded, and activated outside the body before being reintroduced into the patient. By bolstering the immune response with a concentrated dose of tumor-targeting T cells, this therapy seeks to tip the balance in favor of the immune system, enabling it to mount a more effective attack against the cancer.
The Therapeutic Process
The journey of TIL therapy begins with the surgical removal of a tumor specimen from the patient. From this tissue, TILs are isolated using specialized techniques in the laboratory. These extracted T cells are then cultured and expanded to increase their numbers dramatically, creating a robust army of immune cells primed for combat.
Once a sufficient quantity of activated TILs has been generated, they are infused back into the patient's bloodstream. Due to specific molecular signals sent out by cancer cells, these engineered immune cells focus on the tumor site as they travel throughout the body. Upon reaching their destination, the TILs launch a multifaceted assault, directly attacking malignant cells and recruiting other components of the immune system to join the fight.
The Promise of TIL Therapy
One of the most compelling aspects of TIL therapy is its potential to achieve durable responses in patients with advanced or metastatic cancers. Clinical studies have shown promising results across a range of cancer types, including melanoma, cervical cancer, and gastrointestinal malignancies. In some cases, patients who have exhausted conventional treatment options have experienced remarkable tumor regression and prolonged survival following TIL therapy.
Connect with CancerFax if you wish to avail of TIL therapy in China.
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
This document discusses various cancer immunotherapy approaches for treating high grade glial tumors, including tumor immunotherapy using exogenously produced and reinfused cytotoxic T cells, depletion of immunosuppressive Treg cells, genetic production and propagation of T cells carrying tumor-antigen specific T cell receptors, vaccination approaches using peptide vaccines, dendritic cell vaccines, and autologous/whole tumor cell vaccines. It also discusses the advantages and disadvantages of different vaccine types as well as ways to augment antitumor immunity, including through adoptive T cell therapy, checkpoint inhibitors, cytokines, and other agents.
Pharm immuno14&15 cancer & transplantpor
The document summarizes key concepts in immunology related to cancer and organ transplants. It discusses how the immune system can recognize and respond to tumors, mechanisms by which tumors evade immune detection, and approaches to cancer immunotherapy. It also covers immune mechanisms of graft rejection, types of transplants, and strategies to prevent rejection through immunosuppression.
SCT60103 Group 2 Presentation
A normal cell can be transformed into a cancerous cell. Discuss the therapeutic strategies that are employed to target the cellular transformation process for cancer prevention and treatment.
Tumourclasss
1. A tumor is abnormal tissue consisting of genetic-altered cells that can arise due to mutations or environmental factors like radiation or infections.
2. The immune system can recognize and destroy early cancer cells but tumors evolve mechanisms to evade the immune response through loss of antigen presentation or secretion of factors that suppress T cells.
3. Immunotherapy aims to enhance anti-tumor immunity through vaccines, adoptive cell therapies, monoclonal antibodies, or cytokines to help the immune system overcome tumor evasion and eliminate cancer cells in a targeted manner with less toxicity than other treatments.
CAR-T Cell Therapy (Aliakbar Esfahani,Bsc of clinical laboratory sciences)
CAR-T Cell Therapy (Aliakbar Esfahani,Bsc of clinical laboratory sciences)Mashhad University of Medical Sciences
This document discusses CAR-T cell therapy. It provides information on CAR-T cells, including that they are T-cells (CD8+ or CD4+) equipped with a chimeric antigen receptor (CAR) that allows them to target tumor cells. The document outlines the steps of CAR-T cell therapy, which involves leukapheresis to collect T-cells, activating and engineering the T-cells to express the CAR, then infusing the CAR-T cells back into the patient to target tumor cells. The document also discusses components of CARs like co-stimulatory domains that enhance T-cell activation and survival.CAR-T CELLS IN SOLID TUMORS
T cells genetically engineered to express chimeric antigen receptors (CAR) have proven an impressive therapeutic activity in patients with certain subtypes of B cell leukaemia or lymphoma, with promising efficacy also demonstrated in patients with multiple myeloma. However, in patients with solid tumors, objective responses to CAR-T cell therapy remain sporadic and transient. Key challenges relating to CAR T cells include the lack of tumor exclusive target, restricted CAR-T cell trafficking to tumor sites, antigen escape and heterogeneity as well as a highly immunosuppressive microenvironment. In this report, we review the current state of the CAR-T technologies as a clinical treatment in solid tumor and we highlight the preclinical innovative designs of novel CAR T cell products that are being developed to increase and expand the clinical benefits of these treatments in patients with solid malignancies.
Crosstalk Between Cancer Inflammation and Immunity: Host Defense Webinar Seri...
This slidedeck will review the mechanisms of anticancer immune responses, which include immune checkpoints and the cross-talk between cancer cells and the cellular mediators of inflammation and immunity. The impact of gut microbiota in eliciting the immune responses against cancer and modulating the effects of drugs will also be discussed. In addition, we will discuss the roles of long non-coding RNAs (lncRNAs) in cancer progression and immune responses. Research tools and therapeutic strategies are also presented.
Immunological Abnormalities in Liver Carcinoma
1) Hepatocellular carcinoma (HCC) has a poor prognosis and limited treatment options. While immune therapies show promise, the response of HCC has been unsatisfactory due to its immunosuppressive microenvironment.
2) Dendritic cells activate T cells to target cancer cells, but in HCC various immune cells and cytokines like regulatory T cells and TGF-β promote immune suppression.
3) Future therapies aim to modulate this microenvironment through vaccines, adoptive cell transfer, immune checkpoint blockade, and other approaches to achieve effective anti-tumor immunity against HCC.
Ras Vaccine prevents skin cancer (Nasti Timares)JI 2015
This document summarizes research on using vaccination to prevent skin tumors induced by chemical carcinogens like DMBA. The researchers found that DMBA exposure causes a mutation in the H-ras oncogene in preneoplastic skin cells within 24 hours. They developed vaccines targeting the mutant H-ras epitope that generated cytotoxic T cells, which eliminated preneoplastic cells and protected against tumor formation when administered before or after DMBA exposure. Adoptive transfer of cells from vaccinated mice regressed established tumors, overcoming tumor-mediated immunosuppression. These findings support further evaluation of targeting early oncogenic mutations to boost immunosurveillance and block tumor development.
SF AACR submitted abstract
This study monitored in vitro immune responses in a healthy donor to various self-antigens presented using dendritic cells. Adenoviral vectors were used to deliver tumor antigens like melan A/MART-1, gp100, NY-ESO-1, HER2, and cytokeratin 18 or HLA-A2 epitope peptides to antigen presenting cells. Analysis of T cell surface markers, cytokine release, and cytolytic activity revealed that gp100 stimulation led to a predominant IFN+ CD8+ CD56- T cell population within three restimulations, whereas MART-1 stimulation resulted in an equal division of IFN+ cells between CD4+ and CD8+ CD56- T cells. Comprehen
Anticancer immunity 2013
The document discusses anti-cancer immunity from an immune perspective. It covers topics like cancer immunoediting, how cancer cells become resistant to immune elimination, and different anti-cancer immunotherapy strategies. Specifically:
1) Cancers evolve to escape immune detection through a process called immunoediting where immunogenic tumor cells are eliminated, leaving behind immune-resistant cells.
2) Tumor cells can become resistant by losing antigen expression or failing to present antigens on MHC molecules, allowing them to evade T cell attack.
3) Popular immunotherapies include immune checkpoint blockade, adoptive cell transfer, vaccines, and strategies that non-specifically stimulate the immune system.
May r.j.-et-al.-2007-clinical-cancer-research
This document summarizes a study identifying three HLA class II peptide epitopes from the Wilms' tumor 1 (WT1) oncoprotein that stimulate CD4+ T cell responses. One peptide (122-140) also contains a previously identified CD8+ epitope (126-134) and was modified to improve its ability to induce both CD4+ and CD8+ T cell responses against WT1-expressing tumor cells. Dendritic cells pulsed with these WT1 peptides were able to stimulate peptide-specific CD4+ T cell responses and cross-priming experiments showed the dendritic cells could present the peptides after processing tumor cell lysates. These WT1 CD4+ peptides may be useful for inclusion in
Immune cell therapy
Immunotherapy is defined as the approach to treating
cancer by generating or augmenting an immune
response against it.
Genetic deletion of HVEM in a leukemia B cell line promotes a preferential in...
Introduction: A high frequency of mutations affecting the gene encoding Herpes Virus Entry Mediator (HVEM, TNFRSF14) is a common clinical finding in a wide variety of human tumors, including those of hematological origin.
Methods: We have addressed how HVEM expression on A20 leukemia cells influences tumor survival and its involvement in the modulation of the anti-tumor immune responses in a parental into F1 mouse tumor model of hybrid resistance by knocking-out HVEM expression. HVEM WT or HVEM KO leukemia cells were then injected intravenously into semiallogeneic F1 recipients and the extent of tumor dissemination was evaluated.
Results: The loss of HVEM expression on A20 leukemia cells led to a significant increase of lymphoid and myeloid tumor cell infiltration curbing tumor progression. NK cells and to a lesser extent NKT cells and monocytes were the predominant innate populations contributing to the global increase of immune infiltrates in HVEM KO tumors compared to that present in HVEM KO tumors. In the overall increase of the adaptive T cell immune infiltrates, the stem cell-like PD-1- T cells progenitors and the effector T cell populations derived from them were more prominently present than terminally differentiated PD-1+ T cells.
Conclusions: These results suggest that the PD-1- T cell subpopulation is likely to be a more relevant contributor to tumor rejection than the PD-1+ T cell subpopulation. These findings highlight the role of co-inhibitory signals delivered by HVEM upon engagement of BTLA on T cells and NK cells, placing HVEM/BTLA interaction in the spotlight as a novel immune checkpoint for the reinforcement of the anti-tumor responses in malignancies of hematopoietic origin.
Seminar-Oncolytic viruses
This document provides an overview of oncolytic viruses (OVs) as a potential cancer treatment. It discusses how OVs selectively target and kill cancer cells through direct lysis and stimulation of anti-tumor immunity. The mechanisms of OV action and various strategies for enhancing their efficacy are described, such as arming OVs with immunostimulatory genes or anti-angiogenic factors. Several OVs currently in clinical trials are highlighted, including T-VEC which was approved in 2015 for melanoma treatment. The document concludes that OVs show promise as a novel cancer immunotherapy but further research is still needed to address issues like viral resistance and toxicity.
Basics of immunotherapy in colorectal cancer
Basic immunology of colorectal cancer. Highlight the future role of immunotherapy in Colorectal cancer.
Immunological Role of Th-9 cell
This document summarizes a presentation on T-helper 9 (Th9) cells, a relatively new member of the Th cell family. The presentation outlines that Th9 cells differentiate from naive CD4+ T cells in response to TGF-β and IL-4 cytokines. Th9 cells secrete IL-9 and play roles in allergies, parasite expulsion, autoimmune diseases, cancer, and other conditions. While Th9 cells can promote inflammation and tissue damage, they also help expel parasites and inhibit tumor growth. Further research is needed to understand Th9 cell mechanisms and potential immunotherapy applications.
Tumour Immunology
The document discusses cancer immunosurveillance and immunoediting. It describes how the immune system plays an important role in protecting against cancer development through elimination of nascent tumor cells and shaping of tumor immunogenicity. There are three phases - elimination, equilibrium, and escape. In the elimination phase, innate and adaptive immunity work to eliminate cancer cells. In the equilibrium phase, immune editing sculpts less immunogenic tumor cells. Eventually, tumor cells can escape immune destruction in the escape phase through mechanisms to avoid detection.
Tumour immunology
The document discusses cancer immunosurveillance and immunoediting. It describes how the immune system plays an important role in controlling cancer development through 3 phases - elimination, equilibrium, and escape. In the elimination phase, innate and adaptive immunity work to eliminate cancer cells. Some cancer cells may survive this phase if they acquire properties to evade the immune system, entering the equilibrium phase. Eventually, in the escape phase, cancer cells are able to avoid immune destruction through various mechanisms and form clinically detectable tumors. Immunotherapy aims to enhance the immune response against cancer cells.
Similar to immunotherapy and alternative therapy for cancer.pptx (20)
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
CAR-T Cell Therapy (Aliakbar Esfahani,Bsc of clinical laboratory sciences)
CAR-T Cell Therapy (Aliakbar Esfahani,Bsc of clinical laboratory sciences)
Crosstalk Between Cancer Inflammation and Immunity: Host Defense Webinar Seri...
Crosstalk Between Cancer Inflammation and Immunity: Host Defense Webinar Seri...
Ras Vaccine prevents skin cancer (Nasti Timares)JI 2015
Ras Vaccine prevents skin cancer (Nasti Timares)JI 2015
Genetic deletion of HVEM in a leukemia B cell line promotes a preferential in...
Genetic deletion of HVEM in a leukemia B cell line promotes a preferential in...
Recently uploaded
原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样
原版纸张【微信：741003700 】【(carleton毕业证书)卡尔顿大学毕业证】【微信：741003700 】学位证，留信认证（真实可查，永久存档）offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原海外各大学 Bachelor Diploma degree, Master Degree Diploma
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
Equivariant neural networks and representation theory
Or: Beyond linear.
Abstract: Equivariant neural networks are neural networks that incorporate symmetries. The nonlinear activation functions in these networks result in interesting nonlinear equivariant maps between simple representations, and motivate the key player of this talk: piecewise linear representation theory.
Disclaimer: No one is perfect, so please mind that there might be mistakes and typos.
dtubbenhauer@gmail.com
Corrected slides: dtubbenhauer.com/talks.html
Compexometric titration/Chelatorphy titration/chelating titration
Classification
Metal ion ion indicators
Masking and demasking reagents
Estimation of Magnisium sulphate
Calcium gluconate
Complexometric Titration/ chelatometry titration/chelating titration, introduction, Types-
1.Direct Titration
2.Back Titration
3.Replacement Titration
4.Indirect Titration
Masking agent, Demasking agents
formation of complex
comparition between masking and demasking agents,
Indicators/Metal ion indicators/ Metallochromic indicators/pM indicators,
Visual Technique,PM indicators (metallochromic), Indicators of pH, Redox Indicators
Instrumental Techniques-Photometry
Potentiometry
Miscellaneous methods.
Complex titration with EDTA.
Authoring a personal GPT for your research and practice: How we created the Q...
Thematic analysis in qualitative research is a time-consuming and systematic task, typically done using teams. Team members must ground their activities on common understandings of the major concepts underlying the thematic analysis, and define criteria for its development. However, conceptual misunderstandings, equivocations, and lack of adherence to criteria are challenges to the quality and speed of this process. Given the distributed and uncertain nature of this process, we wondered if the tasks in thematic analysis could be supported by readily available artificial intelligence chatbots. Our early efforts point to potential benefits: not just saving time in the coding process but better adherence to criteria and grounding, by increasing triangulation between humans and artificial intelligence. This tutorial will provide a description and demonstration of the process we followed, as two academic researchers, to develop a custom ChatGPT to assist with qualitative coding in the thematic data analysis process of immersive learning accounts in a survey of the academic literature: QUAL-E Immersive Learning Thematic Analysis Helper. In the hands-on time, participants will try out QUAL-E and develop their ideas for their own qualitative coding ChatGPT. Participants that have the paid ChatGPT Plus subscription can create a draft of their assistants. The organizers will provide course materials and slide deck that participants will be able to utilize to continue development of their custom GPT. The paid subscription to ChatGPT Plus is not required to participate in this workshop, just for trying out personal GPTs during it.
Travis Hills' Endeavors in Minnesota: Fostering Environmental and Economic Pr...
Travis Hills of Minnesota developed a method to convert waste into high-value dry fertilizer, significantly enriching soil quality. By providing farmers with a valuable resource derived from waste, Travis Hills helps enhance farm profitability while promoting environmental stewardship. Travis Hills' sustainable practices lead to cost savings and increased revenue for farmers by improving resource efficiency and reducing waste.
Micronuclei test.M.sc.zoology.fisheries.
Current Ms word generated power point presentation covers major details about the micronuclei test. It's significance and assays to conduct it. It is used to detect the micronuclei formation inside the cells of nearly every multicellular organism. It's formation takes place during chromosomal sepration at metaphase.
Unlocking the mysteries of reproduction: Exploring fecundity and gonadosomati...
The pygmy halfbeak Dermogenys colletei, is known for its viviparous nature, this presents an intriguing case of relatively low fecundity, raising questions about potential compensatory reproductive strategies employed by this species. Our study delves into the examination of fecundity and the Gonadosomatic Index (GSI) in the Pygmy Halfbeak, D. colletei (Meisner, 2001), an intriguing viviparous fish indigenous to Sarawak, Borneo. We hypothesize that the Pygmy halfbeak, D. colletei, may exhibit unique reproductive adaptations to offset its low fecundity, thus enhancing its survival and fitness. To address this, we conducted a comprehensive study utilizing 28 mature female specimens of D. colletei, carefully measuring fecundity and GSI to shed light on the reproductive adaptations of this species. Our findings reveal that D. colletei indeed exhibits low fecundity, with a mean of 16.76 ± 2.01, and a mean GSI of 12.83 ± 1.27, providing crucial insights into the reproductive mechanisms at play in this species. These results underscore the existence of unique reproductive strategies in D. colletei, enabling its adaptation and persistence in Borneo's diverse aquatic ecosystems, and call for further ecological research to elucidate these mechanisms. This study lends to a better understanding of viviparous fish in Borneo and contributes to the broader field of aquatic ecology, enhancing our knowledge of species adaptations to unique ecological challenges.
Phenomics assisted breeding in crop improvement
As the population is increasing and will reach about 9 billion upto 2050. Also due to climate change, it is difficult to meet the food requirement of such a large population. Facing the challenges presented by resource shortages, climate
change, and increasing global population, crop yield and quality need to be improved in a sustainable way over the coming decades. Genetic improvement by breeding is the best way to increase crop productivity. With the rapid progression of functional
genomics, an increasing number of crop genomes have been sequenced and dozens of genes influencing key agronomic traits have been identified. However, current genome sequence information has not been adequately exploited for understanding
the complex characteristics of multiple gene, owing to a lack of crop phenotypic data. Efficient, automatic, and accurate technologies and platforms that can capture phenotypic data that can
be linked to genomics information for crop improvement at all growth stages have become as important as genotyping. Thus,
high-throughput phenotyping has become the major bottleneck restricting crop breeding. Plant phenomics has been defined as the high-throughput, accurate acquisition and analysis of multi-dimensional phenotypes
during crop growing stages at the organism level, including the cell, tissue, organ, individual plant, plot, and field levels. With the rapid development of novel sensors, imaging technology,
and analysis methods, numerous infrastructure platforms have been developed for phenotyping.
8.Isolation of pure cultures and preservation of cultures.pdf
Isolation of pure culture, its various method.
Immersive Learning That Works: Research Grounding and Paths Forward
We will metaverse into the essence of immersive learning, into its three dimensions and conceptual models. This approach encompasses elements from teaching methodologies to social involvement, through organizational concerns and technologies. Challenging the perception of learning as knowledge transfer, we introduce a 'Uses, Practices & Strategies' model operationalized by the 'Immersive Learning Brain' and ‘Immersion Cube’ frameworks. This approach offers a comprehensive guide through the intricacies of immersive educational experiences and spotlighting research frontiers, along the immersion dimensions of system, narrative, and agency. Our discourse extends to stakeholders beyond the academic sphere, addressing the interests of technologists, instructional designers, and policymakers. We span various contexts, from formal education to organizational transformation to the new horizon of an AI-pervasive society. This keynote aims to unite the iLRN community in a collaborative journey towards a future where immersive learning research and practice coalesce, paving the way for innovative educational research and practice landscapes.
bordetella pertussis.................................ppt
Bordettela is a gram negative cocobacilli spread by air born drop let
Bob Reedy - Nitrate in Texas Groundwater.pdf
Presented at June 6-7 Texas Alliance of Groundwater Districts Business Meeting
Randomised Optimisation Algorithms in DAPHNE
Slides from talk:
Aleš Zamuda: Randomised Optimisation Algorithms in DAPHNE .
Austrian-Slovenian HPC Meeting 2024 – ASHPC24, Seeblickhotel Grundlsee in Austria, 10–13 June 2024
https://ashpc.eu/
The binding of cosmological structures by massless topological defects
Assuming spherical symmetry and weak field, it is shown that if one solves the Poisson equation or the Einstein field
equations sourced by a topological defect, i.e. a singularity of a very specific form, the result is a localized gravitational
field capable of driving flat rotation (i.e. Keplerian circular orbits at a constant speed for all radii) of test masses on a thin
spherical shell without any underlying mass. Moreover, a large-scale structure which exploits this solution by assembling
concentrically a number of such topological defects can establish a flat stellar or galactic rotation curve, and can also deflect
light in the same manner as an equipotential (isothermal) sphere. Thus, the need for dark matter or modified gravity theory is
mitigated, at least in part.
Cytokines and their role in immune regulation.pptx
This presentation covers the content and information on "Cytokines " and their role in immune regulation .
Recently uploaded (20)
Basics of crystallography, crystal systems, classes and different forms
Basics of crystallography, crystal systems, classes and different forms
Equivariant neural networks and representation theory
Equivariant neural networks and representation theory
Compexometric titration/Chelatorphy titration/chelating titration
Compexometric titration/Chelatorphy titration/chelating titration
Authoring a personal GPT for your research and practice: How we created the Q...
Authoring a personal GPT for your research and practice: How we created the Q...
Travis Hills' Endeavors in Minnesota: Fostering Environmental and Economic Pr...
Travis Hills' Endeavors in Minnesota: Fostering Environmental and Economic Pr...
Unlocking the mysteries of reproduction: Exploring fecundity and gonadosomati...
Unlocking the mysteries of reproduction: Exploring fecundity and gonadosomati...
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
8.Isolation of pure cultures and preservation of cultures.pdf
8.Isolation of pure cultures and preservation of cultures.pdf
Immersive Learning That Works: Research Grounding and Paths Forward
Immersive Learning That Works: Research Grounding and Paths Forward
bordetella pertussis.................................ppt
bordetella pertussis.................................ppt
The binding of cosmological structures by massless topological defects
The binding of cosmological structures by massless topological defects
Cytokines and their role in immune regulation.pptx
Cytokines and their role in immune regulation.pptx
immunotherapy and alternative therapy for cancer.pptx
- 1. Viral vector leukapheresis Isolation of T cells Infection of T cells with viral vector CAR (chimeric antigen receptor) gene Autologous T cell CAR Expansion of CAR T cells CAR T cell culture Activated macrophage Activated Dendritic cell Cancer patient infusion of CAR T cells to patient Immune activation and destruction of tumor cells by CAR T cells Tumor cell Activated NK cell IL-2 IL-12 IL-6 perforins Perforin pore Granzyme Increased expression of death receptors CAR T cell References Feins, S., Kong, W., Williams, E.F., Milone, M.C. and Fraietta, J.A. (2019). An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer. American Journal of Hematology, [online] 94(S1), pp.S3–S9. doi:10.1002/ajh.25418. Li, J., Li, W., Huang, K., Zhang, Y., Kupfer, G. and Zhao, Q. (2018). Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. Journal of Hematology & Oncology, [online] 11(1). doi:10.1186/s13045-018-0568-6. WBCs
- 2. IBRUTINIB IS A NOVEL TARGET THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA Actively stimulation of B-cell receptor is recognized as a critical mechanism contributing to lymphoid malignancies like chronic lymphocytic leukemia. This can be inhibited by Ibrutinib. Figure 01 - Overview of B-cell receptor pathway Figure 02 - Inhibition of Bruton’s tyrosine kinase (BTK) Reference Parmar, S., Patel, K. and Pinilla-Ibarz, J., 2014. Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. Pharmacy and Therapeutics, 39(7), p.483. IBRUTINIB